IsoRay announces a distribution agreement in Canada and another with GE subsidiary Oncura

IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, has announced two new distribution agreements. Inter V Medical of Montreal, Quebec, Canada will have exclusive rights to sell Cesium-131 Brachytherapy seeds in Canada. GE Subsidary, Oncura will distribute the I-125 brachytherapy seed, OncoSeedâ„¢.

In a press release, Dwight Babcock, Chairman and CEO stated, “By adding I-125 seeds to our prostate product offering we can now be a full service provider to our customers. OncoSeed brings with it a substantial and well documented track record of efficacy. While we believe that Cesium-131 adds an important new dimension to brachytherapy for a variety of anatomic sites including prostate, we see strategic value in supporting our customers that have not yet converted all their practice to Cesium-131.”

Related external links (will open a new window):

  • IsoRay, Inc. Announces Iodine Distribution Agreement with GE Subsidary, Oncura
    IsoRay – Richland, Wash. – December 3, 2009
  • IsoRay, Inc. Announces Distribution Agreement in Canada
    IsoRay – Richland, Wash. – November 18, 2009

    Related WTC links:

  • IsoRay is a WTC client

    – end of post –

  • Advertisements
    This entry was posted in Company_and_Client_News, IsoRay, Life_Sciences, Richland, RTD, Southeast. Bookmark the permalink.

    Leave a Reply

    Fill in your details below or click an icon to log in:

    WordPress.com Logo

    You are commenting using your WordPress.com account. Log Out /  Change )

    Google photo

    You are commenting using your Google account. Log Out /  Change )

    Twitter picture

    You are commenting using your Twitter account. Log Out /  Change )

    Facebook photo

    You are commenting using your Facebook account. Log Out /  Change )

    Connecting to %s